Skip to main content

Table 1 BALF analysis and lung function parameters

From: Altered expression of T cell Immunoglobulin-Mucin (TIM) molecules in bronchoalveolar lavage CD4+ T cells in sarcoidosis

  Löfgren's
(n = 26)
Non-Löfgren's
(n = 21)
Controls
(n = 14)
Sex, male/female 12/14 9/12 5/9
Age, yr 39 (25–59)**† 50 (34–75)*** 28 (21–39)
X-ray stage (0/I/II/III) 0/17/8/1 0/5/9/4 (3 ND) 14/0/0/0
BAL analyses    
% recovery 72 (44–82) 67 (44–80) 72 (61–85)
% viability 95 (85–99.6) 95 (82–98.2) 95 (86–98)
Cell concentration (*106/L) 196 (49–588)** 219 (84–746)*** 101 (50–167)
Differential cell counts    
% macrophages 72 (39.4–91)** 62.2 (37–91)*** 87 (65–95)
% lymphocytes 28 (7.6–58)** 34.6 (8.2–61)*** 11 (3.8–29)
% neutrophils 0.9 (0–4.8) 1.0 (0–6.0) 1.6 (0.2–4.4)
% eosinophils 0.2 (0–1.8) 0.5 (0.–4.4) 0.5 (0–1.6)
CD4/CD8 ratio 8.7 (2.4–28.4) 7.2 (0.9–46) ND
HLA-DRB1*0301 20 of 24 (2 ND) 2 of 19 (2 ND) ND
AV2S3 expansion1) 21 of 26 4 of 19 (2 ND) ND
Pulmonary function tests    
VC (% of ref value) 90 (68–126) 78 (53–133) ND
FEV1 (% of ref value) 88 (66–122)† 74 (56–131) ND
DLco (% of ref value) 83 (66–126) 81 (54–106) ND
  1. Data are shown as median (min-max)
  2. VC: Vital Capacity
  3. FEV1: Forced Expiratory Volume in the first second
  4. DLco: Diffusing capacity of the lung for carbon monoxide
  5. **p < 0.01 versus healthy controls
  6. *** p < 0.001 versus healthy controls
  7. † p < 0.05 between patient subgroups
  8. ND, not done
  9. 1) Defined as at least three times higher than the corresponding median value in PBMCs from healthy controls i.e. ≥ 10.5%.